Mackenzie Financial Corp Trims Holdings in QIAGEN (NYSE:QGEN)

Mackenzie Financial Corp trimmed its stake in QIAGEN (NYSE:QGEN) by 5.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 312,635 shares of the company’s stock after selling 17,776 shares during the period. Mackenzie Financial Corp owned about 0.14% of QIAGEN worth $15,125,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA increased its stake in QIAGEN by 38.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 16,339,338 shares of the company’s stock worth $795,563,000 after buying an additional 4,556,336 shares during the period. Senator Investment Group LP purchased a new stake in QIAGEN during the 1st quarter worth approximately $48,690,000. Goldman Sachs Group Inc. increased its stake in QIAGEN by 73.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,279,362 shares of the company’s stock worth $110,982,000 after buying an additional 966,935 shares during the period. Janus Henderson Group PLC increased its stake in QIAGEN by 173.2% during the 1st quarter. Janus Henderson Group PLC now owns 780,513 shares of the company’s stock worth $37,938,000 after buying an additional 494,846 shares during the period. Finally, Premier Fund Managers Ltd increased its stake in QIAGEN by 39.4% during the 2nd quarter. Premier Fund Managers Ltd now owns 1,546,520 shares of the company’s stock worth $76,050,000 after buying an additional 437,391 shares during the period. 52.17% of the stock is currently owned by institutional investors and hedge funds.

QGEN has been the topic of a number of recent analyst reports. Citigroup dropped their price objective on shares of QIAGEN from $65.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday, July 14th. Berenberg Bank reissued a “buy” rating on shares of QIAGEN in a research report on Friday, June 11th. Kepler Capital Markets downgraded shares of QIAGEN from a “buy” rating to a “hold” rating and set a $49.53 price objective on the stock. in a research report on Wednesday, July 14th. Zacks Investment Research downgraded shares of QIAGEN from a “buy” rating to a “hold” rating and set a $57.00 price objective on the stock. in a research report on Thursday, September 16th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of QIAGEN in a research report on Tuesday, June 8th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $54.18.

Shares of QIAGEN stock opened at $54.13 on Friday. The company has a fifty day simple moving average of $53.44 and a 200-day simple moving average of $50.38. QIAGEN has a 12-month low of $45.33 and a 12-month high of $59.00. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 0.65. The stock has a market cap of $12.34 billion, a price-to-earnings ratio of 26.28, a PEG ratio of 1.98 and a beta of 0.21.

QIAGEN (NYSE:QGEN) last issued its quarterly earnings results on Thursday, July 29th. The company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.01. The firm had revenue of $567.31 million during the quarter, compared to analysts’ expectations of $562.35 million. QIAGEN had a net margin of 21.92% and a return on equity of 21.31%. During the same quarter in the prior year, the business earned $0.55 EPS. On average, analysts forecast that QIAGEN will post 2.45 earnings per share for the current fiscal year.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Recommended Story: What is the operating income formula?

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN (NYSE:QGEN).

Institutional Ownership by Quarter for QIAGEN (NYSE:QGEN)

Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.